SLC16A9: A Potential Drug Target and Biomarker (G220963)

Target Name: SLC16A9

NCBI ID: G220963

SLC16A9

SLC16A9: A Potential Drug Target and Biomarker

Solute Carrier Family 16 (SLC16) is a family of transmembrane proteins that play a crucial role in intracellular signaling. The SLC16 family consists of 16 different genes, including SLC16A9, which has been identified as a potential drug target and biomarker. In this article, we will discuss the biology of SLC16A9, its potential as a drug target, and its potential as a biomarker for various diseases.

SLC16A9 gene

The SLC16A9 gene is located on chromosome 16p13.2 and encodes a protein with 214 amino acid residues. The protein has a calculated pI of 9.98 and a predicted localization in the endoplasmic reticulum (ER) membrane. SLC16A9 is a member of the SLC16 family, which is characterized by the presence of a unique transmembrane segment (TMS) and a N-terminal extracellular domain (N-ED).

Function of SLC16A9

SLC16A9 is a member of the SLC16 family, which is involved in intracellular signaling. The SLC16A9 protein is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival.

SLC16A9 functions as a carrier protein for various signaling pathways. It has been shown to be involved in the regulation of T-cell adhesion and migration. SLC16A9 has been shown to mediate the interaction between T cells and adherens endows, which are important for the regulation of T-cell migration.

SLC16A9 has also been shown to be involved in the regulation of cell survival. It has been shown to play a role in the regulation of cell cycle progression, apoptosis, and autophagy. SLC16A9 has been shown to interact with various cellular signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival.

Potential drug target

SLC16A9 is a potential drug target due to its involvement in various cellular signaling pathways. Its involvement in these pathways makes it an attractive target for small molecules that can modulate these signaling pathways.

One of the potential drug targets for SLC16A9 is the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell survival, and small molecules that can inhibit this pathway have been shown to be effective in various diseases, including cancer.

Another potential drug target for SLC16A9 is the T-cell signaling pathway. SLC16A9 has been shown to be involved in the regulation of T-cell adhesion and migration, which are important for the regulation of T-cell function. Small molecules that can modulate this pathway, such as those that target the PD-1 receptor, have been shown to be effective in various diseases, including cancer.

Potential biomarker

SLC16A9 has the potential to serve as a biomarker for various diseases. Its involvement in various cellular signaling pathways makes it an attractive target for small molecules that can modulate these pathways.

One of the potential applications of SLC16A9 as a biomarker is its involvement in cancer. SLC16A9 has been shown to be involved in the regulation of various cellular signaling pathways that are involved in cancer development, including the PI3K/Akt signaling pathway. Small molecules that can inhibit this pathway, such as those that target the PD-1 receptor, have been shown to be effective in

Protein Name: Solute Carrier Family 16 Member 9

Functions: Extracellular pH-and Na(+)-sensitive low-affinity creatine transporter (PubMed:31784090). Functions also as a pH-independent carnitine efflux transporter (PubMed:21886157)

The "SLC16A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets